tiprankstipranks
Trending News
More News >
Stille AB (SE:STIL)
:STIL
Sweden Market

Stille AB (STIL) AI Stock Analysis

Compare
0 Followers

Top Page

SE:STIL

Stille AB

(STIL)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 4o)
Rating:66Neutral
Price Target:
kr239.00
▲(27.81% Upside)
Stille AB's strong financial performance is the primary driver of its stock score, supported by robust revenue growth and cash flow generation. However, technical indicators suggest bearish momentum, and the valuation appears high, limiting the overall score.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective sales strategies, which are crucial for long-term business expansion and sustainability.
Cash Flow Generation
Strong cash flow generation supports future investments and debt servicing, providing financial flexibility and stability for sustained growth.
Balance Sheet Health
A low debt-to-equity ratio indicates prudent financial management, reducing financial risk and enhancing the company's ability to withstand economic fluctuations.
Negative Factors
Net Profit Margin
Lower net profit margins compared to peers may indicate inefficiencies or higher costs, which could impact long-term profitability and competitiveness.
Earnings Growth
Negative EPS growth suggests challenges in translating revenue growth into higher earnings, potentially affecting investor confidence and future investment capacity.
Profitability
Moderate return on equity indicates potential underperformance in generating returns from shareholders' investments, which may limit attractiveness to investors.

Stille AB (STIL) vs. iShares MSCI Sweden ETF (EWD)

Stille AB Business Overview & Revenue Model

Company DescriptionStille AB develops, manufactures, and sells surgical instruments in Sweden and internationally. It offers artery forceps and ligature clamps; bone cutters and rongeurs; clamps, curettes, raspatories, elevators, forceps, and micro instruments; needle holders, and wire twisting and holding forceps; and osteotomes, chisels, retractors and skin hooks, scissors, and other products, as well as c-arm tables. The company also provides ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular surgeries. In addition, it provides instrument repair, maintenance, and inspection services. Further, the company's products are used in various open surgeries. It has a collaboration agreement with GE Healthcare and distribution agreement with Synovis Micro. The company sells through OEM manufacturers of C-frames, distributors, and direct sales. The company was founded in 1841 and is headquartered in Torshälla, Sweden. Stille AB is a subsidiary of Linc AB.
How the Company Makes MoneyStille AB generates revenue through the sale of its surgical instruments and medical devices to hospitals, clinics, and healthcare providers worldwide. The company's revenue model is primarily based on direct sales and distribution partnerships, which allow them to reach a broader market. Key revenue streams include the sale of surgical instruments, instrument sets, and disposable products. Stille also benefits from long-term contracts with healthcare institutions, ensuring a steady flow of income. Additionally, partnerships with other medical technology firms and participation in medical conferences and exhibitions help to enhance their market presence and drive sales.

Stille AB Financial Statement Overview

Summary
Stille AB exhibits strong financial performance with robust revenue growth and efficient operations. The balance sheet is solid, with low debt and strong equity, while cash flow generation is impressive, supporting future investments. However, there is room for improvement in net profit margins.
Income Statement
85
Very Positive
Stille AB demonstrates strong revenue growth with a 16.93% increase in the latest year, supported by healthy gross and net profit margins of 51.87% and 10.21%, respectively. The EBIT and EBITDA margins are robust at 14.87% and 20.87%, indicating efficient operational management. However, the net profit margin shows room for improvement compared to industry leaders.
Balance Sheet
78
Positive
The company's balance sheet is solid, with a low debt-to-equity ratio of 0.09, reflecting prudent financial leverage. The return on equity is moderate at 8.32%, suggesting potential for higher profitability. The equity ratio of 69.87% indicates a strong equity base, enhancing financial stability.
Cash Flow
82
Very Positive
Stille AB's cash flow performance is impressive, with a significant free cash flow growth rate of 217.02%. The operating cash flow to net income ratio of 0.54 and free cash flow to net income ratio of 0.81 highlight effective cash generation relative to earnings. This strong cash flow position supports future investments and debt servicing.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue552.55M569.95M294.89M246.35M187.09M142.63M
Gross Profit289.81M295.64M132.17M111.57M83.46M57.43M
EBITDA87.55M118.97M56.04M44.78M28.89M15.68M
Net Income40.41M58.21M26.65M27.32M16.10M8.27M
Balance Sheet
Total Assets1.06B1.00B804.89M342.55M308.85M164.90M
Cash, Cash Equivalents and Short-Term Investments138.51M158.49M241.45M36.68M27.80M38.12M
Total Debt0.0063.09M62.94M70.77M81.48M24.10M
Total Liabilities362.30M301.70M172.64M152.74M160.75M53.85M
Stockholders Equity692.75M699.40M632.25M189.81M148.10M111.05M
Cash Flow
Free Cash Flow74.13M59.24M24.37M23.89M-11.74M-2.89M
Operating Cash Flow89.06M73.53M37.28M31.94M7.28M20.56M
Investing Cash Flow-84.57M-330.31M-12.90M-8.04M-51.90M-23.44M
Financing Cash Flow40.00M171.40M178.99M-18.54M33.22M-2.75M

Stille AB Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price187.00
Price Trends
50DMA
186.27
Positive
100DMA
203.44
Negative
200DMA
210.80
Negative
Market Momentum
MACD
0.14
Negative
RSI
51.05
Neutral
STOCH
31.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STIL, the sentiment is Neutral. The current price of 187 is below the 20-day moving average (MA) of 187.15, above the 50-day MA of 186.27, and below the 200-day MA of 210.80, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 51.05 is Neutral, neither overbought nor oversold. The STOCH value of 31.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:STIL.

Stille AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
kr1.68B42.2513.36%-20.56%
66
Neutral
kr1.05B45.076.93%-5.80%-65.99%
52
Neutral
kr1.27B196.831.41%21.71%-80.37%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
kr1.28B-28.1338.43%57.76%
48
Neutral
€1.04B-25.61-4.42%13.48%28.98%
43
Neutral
kr848.96M-6.27-36.55%62.24%21.16%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:STIL
Stille AB
190.00
5.50
2.98%
SE:PAX
Paxman AB
53.40
-11.60
-17.85%
SE:SEZI
Senzime AB
5.44
-0.20
-3.55%
SE:CRAD.B
C-Rad AB Class B
31.10
1.20
4.01%
SE:SEDANA
Sedana Medical AB
10.48
-5.52
-34.50%
SE:OSSD
OssDsign AB
11.58
1.50
14.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 23, 2025